254 related articles for article (PubMed ID: 32850405)
1. LC3-Associated Phagocytosis (LAP): A Potentially Influential Mediator of Efferocytosis-Related Tumor Progression and Aggressiveness.
Asare PF; Roscioli E; Hurtado PR; Tran HB; Mah CY; Hodge S
Front Oncol; 2020; 10():1298. PubMed ID: 32850405
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of LC3-associated efferocytosis for the alleviation of intestinal inflammation.
Wu MY; Wang EJ; Ye RD; Lu JH
Autophagy; 2024 Jun; 20(6):1442-1443. PubMed ID: 38311819
[TBL] [Abstract][Full Text] [Related]
3. LC3-Associated Phagocytosis and Inflammation.
Heckmann BL; Boada-Romero E; Cunha LD; Magne J; Green DR
J Mol Biol; 2017 Nov; 429(23):3561-3576. PubMed ID: 28847720
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the Immune Response to Tumor Cell Apoptosis and Efferocytosis.
Werfel TA
Methods Mol Biol; 2022; 2543():45-55. PubMed ID: 36087258
[TBL] [Abstract][Full Text] [Related]
5. Treatment-Induced Tumor Cell Apoptosis and Secondary Necrosis Drive Tumor Progression in the Residual Tumor Microenvironment through MerTK and IDO1.
Werfel TA; Elion DL; Rahman B; Hicks DJ; Sanchez V; Gonzales-Ericsson PI; Nixon MJ; James JL; Balko JM; Scherle PA; Koblish HK; Cook RS
Cancer Res; 2019 Jan; 79(1):171-182. PubMed ID: 30413412
[TBL] [Abstract][Full Text] [Related]
6. LC3-Associated Phagocytosis in Myeloid Cells Promotes Tumor Immune Tolerance.
Cunha LD; Yang M; Carter R; Guy C; Harris L; Crawford JC; Quarato G; Boada-Romero E; Kalkavan H; Johnson MDL; Natarajan S; Turnis ME; Finkelstein D; Opferman JT; Gawad C; Green DR
Cell; 2018 Oct; 175(2):429-441.e16. PubMed ID: 30245008
[TBL] [Abstract][Full Text] [Related]
7. ICAM-1 suppresses tumor metastasis by inhibiting macrophage M2 polarization through blockade of efferocytosis.
Yang M; Liu J; Piao C; Shao J; Du J
Cell Death Dis; 2015 Jun; 6(6):e1780. PubMed ID: 26068788
[TBL] [Abstract][Full Text] [Related]
8. The complex roles of efferocytosis in cancer development, metastasis, and treatment.
Tajbakhsh A; Gheibi Hayat SM; Movahedpour A; Savardashtaki A; Loveless R; Barreto GE; Teng Y; Sahebkar A
Biomed Pharmacother; 2021 Aug; 140():111776. PubMed ID: 34062411
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of efferocytosis through biased FPR2 signaling attenuates intestinal inflammation.
Wu MY; Ge YJ; Wang EJ; Liao QW; Ren ZY; Yu Y; Zhu G; Liu CP; Zhang MN; Su H; Shen HM; Chen Y; Wang L; Wang YT; Li M; Bian Z; Chai J; Ye RD; Lu JH
EMBO Mol Med; 2023 Dec; 15(12):e17815. PubMed ID: 37994307
[TBL] [Abstract][Full Text] [Related]
10. Bioengineered Nanospores Selectively Blocking LC3-Associated Phagocytosis in Tumor-Associated Macrophages Potentiate Antitumor Immunity.
Shang Y; Lu H; Liao L; Li S; Xiong H; Yao J
ACS Nano; 2023 Jun; 17(11):10872-10887. PubMed ID: 37192052
[TBL] [Abstract][Full Text] [Related]
11. Modulation of Osteoblastic Cell Efferocytosis by Bone Marrow Macrophages.
Michalski MN; Koh AJ; Weidner S; Roca H; McCauley LK
J Cell Biochem; 2016 Dec; 117(12):2697-2706. PubMed ID: 27061191
[TBL] [Abstract][Full Text] [Related]
12. Macrophage-Mediated Tumor Cell Phagocytosis: Opportunity for Nanomedicine Intervention.
Zhou X; Liu X; Huang L
Adv Funct Mater; 2021 Jan; 31(5):. PubMed ID: 33692665
[TBL] [Abstract][Full Text] [Related]
13. Efferocytosis in the tumor microenvironment.
Werfel TA; Cook RS
Semin Immunopathol; 2018 Nov; 40(6):545-554. PubMed ID: 30187085
[TBL] [Abstract][Full Text] [Related]
14. Efferocytosis and Its Associated Cytokines: A Light on Non-tumor and Tumor Diseases?
Lin D; Kang X; Shen L; Tu S; Lenahan C; Chen Y; Wang X; Shao A
Mol Ther Oncolytics; 2020 Jun; 17():394-407. PubMed ID: 32346605
[TBL] [Abstract][Full Text] [Related]
15. The clearance of dying cells: table for two.
Green DR; Oguin TH; Martinez J
Cell Death Differ; 2016 Jun; 23(6):915-26. PubMed ID: 26990661
[TBL] [Abstract][Full Text] [Related]
16. Regulation of efferocytosis as a novel cancer therapy.
Zhou Y; Yao Y; Deng Y; Shao A
Cell Commun Signal; 2020 May; 18(1):71. PubMed ID: 32370748
[TBL] [Abstract][Full Text] [Related]
17. Cell Death in the Tumor Microenvironment: Implications for Cancer Immunotherapy.
Gadiyar V; Lahey KC; Calianese D; Devoe C; Mehta D; Bono K; Desind S; Davra V; Birge RB
Cells; 2020 Sep; 9(10):. PubMed ID: 33003477
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-34a Negatively Regulates Efferocytosis by Tissue Macrophages in Part via SIRT1.
McCubbrey AL; Nelson JD; Stolberg VR; Blakely PK; McCloskey L; Janssen WJ; Freeman CM; Curtis JL
J Immunol; 2016 Feb; 196(3):1366-75. PubMed ID: 26718338
[TBL] [Abstract][Full Text] [Related]
19. Glucocorticoids enhance prolonged clearance of apoptotic cells by upregulating liver X receptor, peroxisome proliferator-activated receptor-δ and UCP2.
Garabuczi É; Sarang Z; Szondy Z
Biochim Biophys Acta; 2015 Mar; 1853(3):573-82. PubMed ID: 25523142
[TBL] [Abstract][Full Text] [Related]
20. Efferocytosis of apoptotic human papillomavirus-positive cervical cancer cells by human primary fibroblasts.
Hermetet F; Jacquin E; Launay S; Gaiffe E; Couturier M; Hirchaud F; Sandoz P; Prétet JL; Mougin C
Biol Cell; 2016 Jul; 108(7):189-204. PubMed ID: 27018635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
